ContraFect Corp

22R

Company Profile

  • Business description

    ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.

  • Contact

    28 Wells Avenue
    3rd Floor
    YonkersNY10701
    USA

    T: +1 914 207-2300

    E: [email protected]

    https://www.contrafect.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    23

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,586.7015.300.18%
CAC 407,734.40130.04-1.65%
DAX 4023,629.58369.59-1.54%
Dow JONES (US)41,603.07256.02-0.61%
FTSE 1008,717.9721.29-0.24%
HKSE23,601.2656.950.24%
NASDAQ18,737.21188.53-1.00%
Nikkei 22537,160.47174.600.47%
NZX 50 Index12,596.5065.75-0.52%
S&P 5005,802.8239.19-0.67%
S&P/ASX 2008,360.9012.200.15%
SSE Composite Index3,348.3731.82-0.94%

Market Movers